Business
-
Clinical Trials
Phase I-III Clinical Trials、Real-world Study、Food-effect、DDI -
Regulatory Affairs
Review and Writing of Pharmaceutical R&D Site Documents、Product Site Audit and Inspection、R&D QMS -
Medical Affairs
Clinical Trials Protocol design and writing、PV、Medical Monitoring -
Quality Management
Review and Writing of Pharmaceutical R&D Site Documents、Product Site Audit and Inspection、R&D QMS -
Mass Balance
Provide One-stop Special Services with Value -
Quantitative Pharmacology Analysis
Drug interation and pharmacokinetics in special populations, optimization of initial dose and effective dose -
Biological Detection
preclinical and clinical, radioactive and non-radioactive DMPK studies -
Data Management and Statistical Analysis
Data Management、Biostatistical Analysis Meta Analysis
News
-
2024-09-09GOOD NEWS | Phase 1 clinical trial of the innovative drug OAB-14 of Xinhua Pharmaceutical for the treatment of Alzheimer’s disease successfully completes
On August 22, Xinhua Pharmaceutical convened a summary meeting for the phase 1 clinical study of its innovative drug OAB-14 indicated to treat Alzheimer’s disease (AD) and organized an expert review of the phase 2 clinical study protocol of this product in Beijing.Learn more -
2024-09-09
GOOD NEWS | Yeedozencom assisted Yidu Biotechnology in successfully convening the project kickoff meeting for the phase 4 clinical trial of the “Rabies Vaccine (Vero Cell)”
On July 16, 2024, the kickoff meeting for the phase 4 clinical trial of the freeze-dried human rabies vaccine, initiated by Shandong Yidu Biotechnology Co., Ltd. (hereinafter referred to as “Shandong Yidu”), was successfully convened at the Xuanhan County Center for Disease Control and PreventionLearn more -
2022-07-11GOOD NEWS | Congratulations on the market approval of Fulvestrant Injection of Hangzhou Jiuyuan assisted by Yeedo
On June 28, 2022, Yeedo, as the registered partner of Hangzhou Jiuyuan, successfully helped obtain the marketing approval of "Fluvestrant Injection"( a category 4 drug)!Learn more
Partner
